Nivolumab and Ipilimumab in Advanced Melanoma
N Engl J Med
.
2017 Dec 21;377(25):2503-2504.
doi: 10.1056/NEJMc1714339.
Authors
Jedd D Wolchok
1
,
Linda Rollin
2
,
James Larkin
3
Affiliations
1
Memorial Sloan Kettering Cancer Center, New York, NY wolchokj@mskcc.org
2
Bristol-Myers Squibb, Princeton, NJ
3
Royal Marsden NHS Foundation Trust, London, United Kingdom
PMID:
29262279
DOI:
10.1056/NEJMc1714339
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal
Humans
Ipilimumab*
Melanoma*
Nivolumab
Substances
Antibodies, Monoclonal
Ipilimumab
Nivolumab